- Investing.com
Toho Holdings Co., Ltd. engages in the wholesale distribution of pharmaceutical products in Japan. It operates in four segments: Pharmaceutical Wholesale Business, Dispensing Pharmacy Business, Pharmaceutical Manufacturing and Sales Business, and Other Peripheral Businesses. The company sells pharmaceuticals, narcotics, reagents, and medical devices to hospitals, clinics, and dispensing pharmacies. It is also involved in the management of the dispensing pharmacies business; operates health insurance pharmacy; provision of support home medical care services; peripheral businesses; core system operations; and real estate agency business. In addition, the company manufacture and sell pharmaceuticals; sells generic drugs; and manufactures injection drugs on consignment. Further, it provides support services, including the development and sale of customer support systems, assistance in the start-up of medical institutions and pharmacies, management consulting services, medical support, and personnel recruitment. Additionally, the company offers various customer support systems, including ENIF, an information terminal for pharmaceutical ordering; ENI-Pharmacy, a support system for the separation of dispensing and prescribing functions; LXMATE Helios a medical care appointment system; KAITOS, an online medical consultation and medication guidance system; ENIFwin Nex-Sus, an inventory control system for large hospitals ENIFvoice SP/ ENIFvoice SP + A/ ENIFvoice Core, a supporting system for electronic medication history recording with voice recognition. The company was incorporated in 1948 and is headquartered in Chuo, Japan.
Metrics to compare | 8129 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship8129PeersSector | |
---|---|---|---|---|
P/E Ratio | 15.7x | 15.5x | −0.7x | |
PEG Ratio | 2.53 | 0.07 | 0.00 | |
Price/Book | 1.3x | 1.2x | 2.6x | |
Price / LTM Sales | 0.2x | 0.6x | 3.4x | |
Upside (Analyst Target) | −8.4% | 0.0% | 35.5% | |
Fair Value Upside | Unlock | 28.2% | 3.3% | Unlock |